Shattuck Labs, Inc. (NASDAQ:STTK) Receives $6.20 Consensus PT from Analysts

Shattuck Labs, Inc. (NASDAQ:STTK) has earned a consensus rating of “Hold” from the seven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $6.20.

STTK has been the subject of a number of recent analyst reports. Citigroup raised their price target on shares of Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a report on Tuesday, January 6th. HC Wainwright raised Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a research report on Thursday, January 22nd. Finally, Piper Sandler assumed coverage on Shattuck Labs in a report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price target for the company.

Shattuck Labs Trading Up 5.6%

NASDAQ:STTK opened at $3.77 on Thursday. Shattuck Labs has a twelve month low of $0.69 and a twelve month high of $4.89. The company has a market cap of $238.57 million, a price-to-earnings ratio of -3.70 and a beta of 1.52. The stock has a fifty day simple moving average of $3.69 and a 200-day simple moving average of $2.37.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The firm had revenue of $1.00 million during the quarter. As a group, equities research analysts predict that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of STTK. Aberdeen Group plc raised its holdings in shares of Shattuck Labs by 462.1% in the 4th quarter. Aberdeen Group plc now owns 531,177 shares of the company’s stock valued at $1,939,000 after buying an additional 436,673 shares during the period. Mallini Complete Financial Planning LLC acquired a new position in Shattuck Labs in the 4th quarter valued at about $83,000. Keel Point LLC acquired a new position in Shattuck Labs in the 3rd quarter valued at about $110,000. Bank of America Corp DE increased its stake in Shattuck Labs by 2,968.2% during the third quarter. Bank of America Corp DE now owns 1,131,888 shares of the company’s stock worth $2,705,000 after purchasing an additional 1,094,997 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Shattuck Labs during the third quarter worth about $38,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.